These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 33955331)

  • 1. Identification and validation of potent Mycobacterial proteasome inhibitor from Enamine library.
    Tyagi R; Srivastava M; Singh B; Sharma S; Pandey RP; Asthana S; Kumar D; Raj VS
    J Biomol Struct Dyn; 2022; 40(19):8644-8654. PubMed ID: 33955331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Development of potential proteasome inhibitors against
    Tyagi R; Srivastava M; Jain P; Pandey RP; Asthana S; Kumar D; Raj VS
    J Biomol Struct Dyn; 2022 Mar; 40(5):2189-2203. PubMed ID: 33074049
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Jagadeb M; Rath SN; Sonawane A
    J Biomol Struct Dyn; 2019 Aug; 37(13):3388-3398. PubMed ID: 30132739
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of new
    Mehra R; Chib R; Munagala G; Yempalla KR; Khan IA; Singh PP; Khan FG; Nargotra A
    Mol Divers; 2015 Nov; 19(4):1003-19. PubMed ID: 26232029
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel multitarget antitubercular inhibitors against mycobacterial peptidoglycan biosynthetic Mur enzymes by structure-based virtual screening.
    Kumari M; Subbarao N
    J Biomol Struct Dyn; 2022 Nov; 40(18):8185-8196. PubMed ID: 33826470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of glucosyl-3-phosphoglycerate phosphatase as a novel drug target against resistant strain of Mycobacterium tuberculosis (XDR1219) by using comparative metabolic pathway approach.
    Uddin R; Zahra NU; Azam SS
    Comput Biol Chem; 2019 Apr; 79():91-102. PubMed ID: 30743161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of New
    Almeleebia TM; Shahrani MA; Alshahrani MY; Ahmad I; Alkahtani AM; Alam MJ; Kausar MA; Saeed A; Saeed M; Iram S
    Molecules; 2021 Apr; 26(8):. PubMed ID: 33923734
    [No Abstract]   [Full Text] [Related]  

  • 8. Screening of Antitubercular Compound Library Identifies Inhibitors of Mur Enzymes in
    Eniyan K; Rani J; Ramachandran S; Bhat R; Khan IA; Bajpai U
    SLAS Discov; 2020 Jan; 25(1):70-78. PubMed ID: 31597510
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carfilzomib as a potential inhibitor of NADH-dependent enoyl-acyl carrier protein reductases of
    Mahfuz AMUB; Stambuk Opazo F; Aguilar LF; Iqbal MN
    J Biomol Struct Dyn; 2022 Jun; 40(9):4021-4037. PubMed ID: 33251968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Current status and perspective on drug targets in tubercle bacilli and drug design of antituberculous agents based on structure-activity relationship.
    Tomioka H
    Curr Pharm Des; 2014; 20(27):4305-6. PubMed ID: 24245755
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exploring biogenic chalcones as DprE1 inhibitors for antitubercular activity via in silico approach.
    Rathod S; Chavan P; Mahuli D; Rochlani S; Shinde S; Pawar S; Choudhari P; Dhavale R; Mudalkar P; Tamboli F
    J Mol Model; 2023 Mar; 29(4):113. PubMed ID: 36971900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
    Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
    Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of new benzamide inhibitor against α-subunit of tryptophan synthase from Mycobacterium tuberculosis through structure-based virtual screening, anti-tuberculosis activity and molecular dynamics simulations.
    Naz S; Farooq U; Ali S; Sarwar R; Khan S; Abagyan R
    J Biomol Struct Dyn; 2019 Mar; 37(4):1043-1053. PubMed ID: 29502488
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification of potential non-nucleoside MraY inhibitors for tuberculosis chemotherapy using structure-based virtual screening.
    Pandey P; Chatterjee S; Berida T; Doerksen RJ; Roy S
    J Biomol Struct Dyn; 2022 Jul; 40(11):4832-4849. PubMed ID: 33353500
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Development of antituberculous drugs: current status and future prospects].
    Tomioka H; Namba K
    Kekkaku; 2006 Dec; 81(12):753-74. PubMed ID: 17240921
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Screening of antitubercular compound library identifies novel ATP synthase inhibitors of Mycobacterium tuberculosis.
    Kumar S; Mehra R; Sharma S; Bokolia NP; Raina D; Nargotra A; Singh PP; Khan IA
    Tuberculosis (Edinb); 2018 Jan; 108():56-63. PubMed ID: 29523328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Virtual screening to identify novel potential inhibitors for Glutamine synthetase of
    Kumari M; Subbarao N
    J Biomol Struct Dyn; 2020 Oct; 38(17):5062-5080. PubMed ID: 31755360
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of potent chemical antituberculosis agents targeting Mycobacterium tuberculosis acetohydroxyacid synthase.
    Jung IP; Ha NR; Lee SC; Ryoo SW; Yoon MY
    Int J Antimicrob Agents; 2016 Sep; 48(3):247-58. PubMed ID: 27451857
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Computational discovery of potent drugs to improve the treatment of pyrazinamide resistant Mycobacterium tuberculosis mutants.
    Jagadeb M; Rath SN; Sonawane A
    J Cell Biochem; 2018 Sep; 119(9):7328-7338. PubMed ID: 29761826
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the Potential Inhibition of Candidate Drug Molecules for Clinical Investigation Based on their Docking or Crystallographic Analyses against
    Dey R; Nandi S; Samadder A; Saxena A; Saxena AK
    Curr Top Med Chem; 2020; 20(29):2662-2680. PubMed ID: 32885754
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.